Citius Oncology (CTOR) Q3 2026 earnings summary

Executive summary

• Commercial launch of LYMPHIR began in December 2025, with expanding adoption in U.S. oncology centers and initial shipments to Europe through distribution partners.

• Achieved $7.1 million in revenue for the nine months ended June 30, 2026, driven by the ongoing launch of LYMPHIR and expanding institutional demand.

• Institutional vial orders for LYMPHIR grew 31% sequentially, with 44 institutions ordering since launch and July marking the largest monthly order to date.

• The company faces significant liquidity challenges, with a net loss of $41.1 million for the nine months ended June 30, 2026, and negative working capital of $16.1 million.

• Financing activities included a $10 million term loan and $9.7 million from warrant exercises in May 2026.

Financial highlights

• Revenue for Q3 2026 was $1.5 million, with gross profit margin of 67%.

• Nine-month revenue reached $7.1 million, with a gross profit margin of 77%.

• Net loss for Q3 2026 was $8.9 million ($0.08 per share), and for the nine months ended June 30, 2026, was $41.1 million ($0.42 per share), both higher than the prior year periods.

• Cash and cash equivalents at June 30, 2026, were $16.6 million.

• Operating expenses for the nine months ended June 30, 2026, were $48.1 million, up from $18.8 million year-over-year, driven by a $19.7 million contract cancellation fee and increased commercial buildout.

Outlook and guidance

• Management expects continued growth in institutional demand and wholesaler orders for LYMPHIR, with confidence in a robust remainder of fiscal 2026.

• Additional capital will be required to support operations beyond November 2026, with ongoing efforts to raise funds and evaluate strategic alternatives.